Alpha 2.0
Login Register
» Authors » Laure Vincent

Laure Vincent

Explore the profile of Laure Vincent including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 53
Citations 539
Followers 0
Related Specialties
Hematology
Oncology
General Surgery
Top 10 Co-Authors
Guillaume Cartron
Jerome Moreaux
Philippe Moreau
Aurore Perrot
Lionel Karlin
Xavier Leleu
Nicolas Robert
Guilhem Requirand
Mohamad Mohty
Salomon Manier
Published In
Haematologica
Bone Marrow Transplant
Br J Haematol
Oncotarget
Blood
Affiliations
Soon will be listed here.
Recent Articles
1.
Real-World Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated Before the Era of Anti-CD38 Antibodies: The EMMY Cohort From 2017 to 2020
Vincent L, Decaux O, Perrot A, Royer B, Chalopin T, Bobin A, et al.
Cancer Med . 2025 Mar; 14(6):e70619. PMID: 40087879
Aims/background: Recent agents have profoundly reshaped the multiple myeloma (MM) landscape. Their real-world impacts need to be assessed over the long term. Methods: EMMY is a non-interventional, prospective dynamic cohort,...
2.
Dexamethasone added to induction and post-remission therapy in older patients with newly diagnosed acute myeloid leukemia: a multicenter, phase II trial (DEXAML-02)
Bertoli S, Berard E, Peterlin P, Guieze R, Desbrosses Y, Hicheri Y, et al.
Haematologica . 2025 Feb; PMID: 39911128
Not available.
3.
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone Induction in Newly Diagnosed Myeloma: Analysis of the MIDAS Trial
Perrot A, Touzeau C, Lambert J, Hulin C, Caillot D, Karlin L, et al.
Blood . 2025 Jan; PMID: 39841461
In patients with transplant-eligible newly diagnosed multiple myeloma, induction therapy with a quadruplet regimen prior to autologous transplant is the standard of care. The phase III IFM2020-02-MIDAS study (NCT04934475) assessed...
4.
Teclistamab in relapsed refractory multiple myeloma: a multi-institutional real-world study from the French early access program
Perrot A, Hulin C, Boumendil A, Manjra H, Leveque A, Croizier C, et al.
Haematologica . 2024 Nov; PMID: 39568438
Not available.
5.
Ixazomib, pomalidomide and dexamethasone in relapsed or refractory multiple myeloma characterized with highrisk cytogenetics: the IFM 2014-01 study
Bobin A, Manier S, De Keizer J, Srimani J, Hulin C, Karlin L, et al.
Haematologica . 2024 Nov; 110(3):758-763. PMID: 39540213
No abstract available.
6.
LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed/refractory multiple myeloma - 2-year follow-up (final analysis)
Mateos M, Weisel K, De Stefano V, Goldschmidt H, Delforge M, Mohty M, et al.
Leukemia . 2024 Sep; 38(12):2554-2560. PMID: 39322709
Treatment of relapsed/refractory multiple myeloma (RRMM) is challenging as patients exhaust all available therapies and the disease becomes refractory to standard drug classes. Here we report the final results of...
7.
Long-term outcome after allogeneic stem cell transplantation for GATA2 deficiency: An analysis of 67 adults and children from France and Belgium
Sicre de Fontbrune F, Chevillon F, Fahd M, Desseaux K, Poire X, Forcade E, et al.
Br J Haematol . 2024 Aug; PMID: 39159950
Modalities and timing of haematopoietic stem cell transplant (HSCT) in patients with GATA2 deficiency are still subject to debate. On June 2022, 67 patients (median age 20.6 years) underwent a...
8.
The EMMY longitudinal, cohort study: real-world data to describe multiple myeloma management and outcomes as more therapeutic options emerge
Decaux O, Garlantezec R, Belhadj-Merzoug K, Macro M, Frenzel L, Perrot A, et al.
Clin Hematol Int . 2024 Jul; 6(3):22-27. PMID: 39050939
The therapeutic management of patients with multiple myeloma (MM) is complex. Despite substantial advances, MM remains incurable, and management involves cycles of treatment response, disease relapse, and further therapy. Currently,...
9.
Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial
Leleu X, Hulin C, Lambert J, Bobin A, Perrot A, Karlin L, et al.
Nat Med . 2024 Jun; 30(8):2235-2241. PMID: 38830994
CD38-targeting immunotherapy is approved in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma (NDMM) that are transplant ineligible (TI) and is considered the best standard of...
10.
Long-term outcomes and renal responses following autologous hematopoietic stem cell transplantation for light chain deposition disease: a retrospective study on behalf of the Chronic Malignancies Working Party of the European Society for Blood and...
Garderet L, Gras L, Koster L, De Wreede L, Montserrat R, Vincent L, et al.
Haematologica . 2024 Mar; 109(8):2619-2627. PMID: 38546696
There is little long-term outcome data on the efficacy of autologous hematopoietic stem cell transplantation (ASCT) in light chain deposition disease (LCDD). We identified 51 LCDD patients in the European...